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Exosomes are cell-secreted nanovesicles (40!200 nm) that represent a rich source of novel biomarkers in the
diagnosis and prognosis of certain diseases. Despite the increasingly recognized relevance of these vesicles
as biomarkers, their detection has been limited due in part to current technical challenges in the rapid
20 isolation and analysis of exosomes. The complexity of the development of analytical platforms relies on the
heterogeneous composition of the exosome membrane. One of the most attractive tests is the inmunochro-
matographic strips, which allow rapid detection by unskilled operators. We have successfully developed a novel
lateral flow immunoassay (LFIA) for the detection of exosomes based on the use of tetraspanins as targets.
We have applied this platform for the detection of exosomes purified from different sources: cell culture
25 supernatants, human plasma and urine. As proof of concept, we explored the analytical potential of this LFIA
platform to accurately quantify exosomes purified from a human metastatic melanoma cell line. The one-step
assay can be completed in 15min, with a limit of detection of 8.54"105 exosomes/mLwhen ablend of anti-CD9
and anti-CD81 were selected as capture antibodies and anti-CD63 labelledwith gold nanoparticles as detection
antibody. Based on our results, this platform could be well suited to be used as a rapid exosome quantification
30 tool, with promising diagnostic applications, bearing in mind that the detection of exosomes from different
sources may require adaptation of the analytical settings to their specific composition.
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E
xtracellular vesicles (EVs) consist of small, bubble-
like membranous structures that are released from
45 cells in 3 primary types: exosomes, microvesicles
and apoptotic bodies (1), and play a pivotal role in inter-
cellular communication. These vesicles have been studied
over the years using a variety of isolation strategies and
have been classified according to their distinct structural
50 and biochemical properties. Exosomes are defined as
40!200 nm diameter (2) membrane vesicles of endocytic
origin that are released by most cell types upon fusion of
multivesicular bodies (MVBs) with the plasma membrane
(3,4). The protein content of exosomes has been exten-
55 sively analysed from different cell types and body fluids by
mass spectrometry, western blotting, flow cytometry and
immunoelectron microscopy and includes both conserved
and cell-type-specific proteins. All EVs contain proteins
involved inmembrane transport and fusion (RabGTPases
60 and annexins), heat shock proteins (HSP60,HSP70,HSPA5
and HSP90), integrins and variable proportions of tetra-
spanins (CD63, CD81 and CD9) (4!6). Moreover, EVs
also contain a variety of nucleic acids including DNA,
mRNA and miRNA. A recent comparative proteomic
65 study between different subtypes of EVs (5) proposed that
co-expression of CD63 with at least one other tetraspanin,
CD9 and/or CD81, characterized exosomes of endosomal
origin, also enriched in proteins involved in MVB biogen-
esis (e.g. TSG101), whereas other co-isolated small EVs
70 bearing a single or no tetraspanins originated from other
intracellular locations.
Exosomes and other EVs are present in many biological
fluids, such as serum/plasma, urine, amniotic fluid, cere-
brospinal fluid and saliva (7). Since they carry cell-specific
75 signatures, EVs that are secreted into biological fluids have
tremendous potential as biomarkers for prognosis and
monitoring the response to treatment in a range of
diseases including vascular disorders, autoimmune and
hematologic diseases, and cancer (1,8). Moreover, analysis
80 of EVs from body fluids may serve as a non-invasive
alternative to the current diagnostic tests. In fact, early
reports suggest that EVs may be of use as a ‘‘liquid
biopsy’’ (9). In general, higher EVs content has been found
in patients with advanced cancer compared to healthy
85 donors, although more studies are needed in this context
(10,11).
Although this branch of science is growing very fast,
there are still limitations in relation to isolation and puri-
fication technologies as well as to the ability to measure
90 EVs sizes, concentration and molecular content, and only
a few EV-based diagnostic assays are currently available
(12!14). The ‘‘gold standard’’ and most commonly used
protocol for EVs isolation and purification is differential
centrifugation, which involves sequential centrifugation
95 and ultracentrifugation steps (15). Recently, several alter-
native methods have been introduced for isolation and
purification of EVs, including antibody-coated magnetic
beads, microfluidic devices (16,17), precipitation methods
and filtration technologies (8,18). After EVs isolation,
100many downstream applications require EVs quantitation.
For this, researchers use a standard ELISA approach
(8,10,19). As an alternative to ELISA, lab-on-a-chip
devices are useful techniques in clinical care for medical
diagnosis, since they allow the use of small volumes of
105sample and shorter processing times, improve sensitivity
and reduce clinical care costs. These miniaturized devices
integrate microfluidic approaches that enable on-chip
immune isolation and in situ protein analysis of EVs
directly from patient plasma (20) and allow multiplex
110assays (21). Indeed, Chen et al. (22) have developed a
point-of-care (POC) system for microvesicle analysis
using a paper-based ELISA device, which enables the
use of very low sample and reagent volumes and that is
completed in 10 min. The Lee and Weissleder group has
115developed small devices that allow quantification of EVs
based on different physicochemical principles, such as
nuclear magnetic resonance (23), surface plasmon reso-
nance (24) and electrochemical measurements combined
with immunocapture (25).
120Within the POC systems, lateral flow immunoassay
tests (LFIA) represent a well-established technology,
which fulfils the characteristics of a rapid, simple and
cost-effective test capable of being performed by unskilled
operators (26). LFIA is based on the recognition of one or
125more analytes (multiplex) of interest by using antibodies.
These antibodies are immobilized on a nitrocellulose
membrane and interact with the analyte when the sample
is applied and flows by capillary action. In a sandwich
format, protein!target complexes and free capture anti-
130bodies, both labelled, accumulate in 2 defined regions
forming the test and control line, respectively. The main
advantage compared with other immunoassays is that the
entire test can be done usually in one step and in a few
minutes (27). To the authors’ knowledge, this type of test
135had not yet been developed for the detection of exosomes.
This might reflect the difficulty of dealing with vesicles
of this size that have a heterogeneous composition on
the membrane, in highly complex biological matrixes.
However, LFIAs have been successfully developed for
140analytes reaching a size of 1 mm, such as spores and
bacteria (28,29).
In this study, LFIA platforms for the detection of exo-
somes have been developed using tetraspanins as targets
for capture and detection antibodies. Tetraspanins CD9,
145CD63 and CD81 are specially enriched in the membrane
of exosomes (5,30), and they are often used as exosome
biomarkers due to their high abundance in virtually any
cell type. However, their single expression on an EV does
not demonstrate its endosomal origin (5): the approach
150developed here allows to analyse specifically EVs bear-
ing at least 2 of these 3 tetraspanins, and thus more
specifically bona fide exosomes, rather than other EVs.
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Methods
Cell culture
155 The human melanoma cell line Ma-Mel-86c was estab-
lished from a stage IV metastatic lymph node lesion (31).
Small tissue pieces were distributed in cell culture dishes,
and outgrowing cells were split for the first time at 90%
cell confluence. Melanoma cell lines were cultured in
160 RPMI-1640 medium supplemented with L-glutamine, 10%
foetal bovine serum (FBS) and penicillin/streptomycin.
Cells were cultured at 378C in a 5% CO2 atmosphere.
Tumour tissue was collected after approval by the insti-
tutional review board and patient informed consent.
165 Antibodies
Anti-tetraspanin antibodies used for ELISA and LFIA
in this study have been previously characterized (32):
anti-CD9 VJ1/20 (33) and anti-CD63 Tea3/18 (34).
Anti-CD81 5A6 was provided by Dr. S. Levy (Department
170 of Oncology, Stanford University School of Medicine,
Stanford, CA). Antibodies were purified by affinity
chromatography with Prot-G Sepharose (GE Healthcare
Life Sciences) and biotinylated with Sulfo-NHS Biotin
(Pierce). Free biotin was eliminated by overnight dialysis
175 against PBS buffer.
Tetraspanin antibodies used for western blot (MEM-63,
MEM-81 andMEM-9) were obtained from Vaclav Horejsi
(Czech Republic).
Exosomes purification and evaluation of protein
180 concentration
For exosome isolation, cells were cultured in medium
supplemented with 0.5% exosome-free FBS for 3!5 days.
Cells were centrifuged for 10 min at 200"g and exo-
somes purified by sequential centrifugation as pre-
185 viously described (35). Exosome-free FBS was prepared
by ultracentrifugation of regular FBS, during 16!18 h at
100,000"g followed by filter sterilization. Aliquots were
prepared and kept frozen at#208C.
Briefly, after centrifugation of cells, supernatants were
190 centrifuged twice at 500"g for 10 min. Supernatants were
pooled and centrifuged at 10,000"g for 30 min prior to
exosomes isolation by ultracentrifugation at 100,000"g
for 2 h at 48C (Beckman Instruments). Exosomes were
resuspended in HEPES-buffered saline buffer (HBS: 10 mM
195 HEPES pH 7.2, 150 mM NaCl).
Purified exosomes were supplemented with sucrose to
a final concentration of 8% and frozen immediately at
#808C and lyophilized using a Flexi-Dry Lyophilizer
(FTS Systems).
200 Lyophilized commercial exosomes purified from plasma
(HBM-PEP) and urine (HBM-PEU) of healthy donors
were purchased from HansaBioMed (Tallinn, Estonia)
used in LFIAs. The expression of the tetraspanins CD9,
CD63 and CD81 was confirmed by western blot and flow
205 cytometry using, respectively, antibodies anti-CD9, anti-
CD63 and anti-CD81 (HansaBioMed, Tallinn, Estonia)
(Supplementary Figs. 1 and 2). Exosome pellets were
resuspended in deionized water (Milli-Q), following the
manufacturer’s instructions.
210For analysis of protein concentration, Bradford
assays were performed, following the manufacturer’s
recommendations.
The concentration of Ma-Mel-86c exosomes was also
determined by nanoparticle tracking analysis (NTA) in a
215NanoSight NS500 (Malvern Instruments Ltd, Malvern,
UK). A 405-nm laser beam was used to highlight the par-
ticles, which act as point scatters. Analysis was performed
using the NTA 3.1 software (Malvern). The experiment
was carried out at the laboratory of Dr. H. Peinado,
220Spanish National Centre for Oncological Research
(CNIO).
Western blot
Cell lysates were prepared by incubation in Tris pH
7.6 buffer containing 150 mM NaCl, 5 mM EDTA, 1%
225NP-40 and the protease inhibitors leupeptin and pepstatin
for 30 min at 48C. Nuclei were eliminated by centrifuga-
tion at 13,000"g. Lysates and purified exosomes were
resuspended in Laemmli buffer and run on 12% SDS-
PAGE gels. For detection of tetraspanins, samples were
230run under non-reducing conditions. Proteins were trans-
ferred to Immobilon-P (Millipore) membrane. The mem-
brane was blocked using PBS containing 0.1% Tween-20
(PBS-T) and 5% non-fat dry milk. Tetraspanins were detec-
ted by incubation with the antibodies indicated above,
235followed by HRP-conjugated secondary antibody. Proteins
were visualized using the ECL system (GE Healthcare).
Transmission electron microscopy
Lyophilized exosomes were reconstituted and diluted 1:20
with PBS. Electron microscope examination of exosomes
240was carried out by floating a carbon-coated 400-mesh
Formvar EM grid on top of 1 drop of freshly prepared
exosomes (60 mg/mL in PBS) for about 1 min. The grid
was then briefly washed with deionized water and floated
on a drop of 2% uranyl acetate. Samples were examined
245using a Jeol JEM 1011 electron microscope operating at
100 kV with a CCD camera Gatan Erlangshen ES1000W.
The experiment was carried out at the Electron Micro-
scopy Facility, Spanish National Centre for Biotechnology
(CNB).
250Size distribution and z-potential
Size distribution and z-potential assays were carried out
with both fresh and lyophilized samples using a Zetasizer
Nano ZS ZEN3600 (Malvern Instruments, Malvern, UK)
equipped with a solid-state He-Ne laser (l$633) for
255monitoring the conjugation process. Diluted (50- to 100-
fold) fractionswere loaded in the cell. A total of 3 readings
were performed at 258C. Each reading was composed of
15 measurements of the backscattering (1738) intensity.
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Zetasizer software version 7.03 was used for data proces-
260 sing and analysis.
ELISA for exosome detection
In order to test the recognition of different molecules in
the same exosome sample, and before testing the LFIA
system, different combinations of tetraspanin-specific anti-
265 bodies were tested by ELISA. Ninety-six well plates
(Falcon) were coated with the indicated antibodies (100 mL
at 5.0 mg/mL) in either 100 mM sodium borate buffer, pH
9, or 100 mM sodium carbonate buffer, pH 9.6, over-
night at 48C. Wells were washed with HBS and blocked
270 with 200 mL/well (2% BSA in HBS) for 1 h at 378C.
Following 3 washes, exosomes purified from Ma-Mel-86c
cell culture supernatants were added (100 mL/well) and
incubated at 378C for 2 h. HBS was used as a nega-
tive control. After 3 washes with HBS, the indicated
275 amount of secondary biotinylated antibodies (anti-CD9,
anti-CD81 or anti-CD63) was added and incubated for
1 h at 378C. After 3 washes with HBS, the plate was
incubated with 100 mL of HRP-conjugated streptavidin
(Biolegend) diluted 1:2,000 at 378C for 1 h. After 3 final
280 washes, the reaction was developed with ABTS for 1 h
(Roche) and optical densities were recorded at 405 nm
with a reference of 490 nm, using a Sunrise absorbance
reader (Tecan).
Lateral flow immunoassay
285 Gold nanoparticles of size 40 nm (AuNP) were purcha-
sed from BB International (UK). Nitrocellulose mem-
branes (HF07504XSS) and glass fibre sample pads
(GFCP001000) were purchased fromMillipore (Germany).
Other materials used were backing cards (KN-V1080,
290 Kenoshatapes, the Netherlands) and absorbent pads
(Whatman, USA). The running buffer consisted of
10 mM HEPES, pH 7.4, with 150 mM NaCl, 0.05%
Tween-20 and 1% BSA.
An IsoFlow reagent dispensing system (Imagene
295 Technology, USA) was used to dispense the detection
lines (dispense rate 0.100 mL/mm) and the strips were cut
with a guillotine Fellowes Gamma (Spain).
Labelling antibody with colloidal gold
Anti-CD9 monoclonal antibody (Clone VJ1/20) and anti-
300 CD63 monoclonal antibody (Clone Tea3/18) were conju-
gated to AuNP. In order to find the optimal concentration
of the antibody to stabilize the gold nanoparticles, a gold
colloid titration procedure was followed (36). In the case
of anti-CD9, aggregation of gold nanoparticles occurred
305 even though different concentrations of antibody and
different buffers were tested. For this reason, 2 dif-
ferent conjugation protocols were carried out: (a) a
non-covalent process for anti-CD63 and (b) a covalent
protocol for anti-CD9.
310a. Non-covalent process: 100 mL of 150 mg/mL anti-
CD63 (Clone Tea3/18) was added to 1.5 mL of AuNP
suspension. After shaking for 1 h, 100 mL of blocking
solution (1 mg/mL BSA in PBS 10 mM, pH 7.4) was
added to block the residual surfaces of antibody-
315colloidal gold conjugate. After 20 min of reaction, the
mixture was centrifuged at 6,800"g for 20 min. The
supernatant was discarded and the pellet was resus-
pended in 2 mM borate buffer, pH 7.4, with 10% suc-
rose and 1% BSA. The product (AuNPs-anti-CD63
320conjugate) was then stored at 48C until used.
b. Covalent protocol: Conjugation of AuNP with anti-
CD9 monoclonal antibody (Clone VJ1/20) was carried
out using 3,3?-dithiobis[sulfosuccinimidylpropionate]
(DTSSP) as a bifunctional cross linker, adapted from
325a previously reported procedure (37). 10 mL of 1 mM
DTSSP was added to 1.0 mL of AuNP and mixed for
30 min. The suspension was then centrifuged at
3,300"g for 5 min. The supernatant was discarded
and the pellet was resuspended in 2 mM borate buffer
330(pH 8.9). Then, 15 mg of anti-CD9 was added to the
AuNP, shaken for 1.5 h and the solution centrifuged
at 6,800"g for 20 min. The supernatant was discar-
ded and the pellet was resuspended in 2 mM borate
buffer containing 1% BSA. The product (AuNPs!
335anti-CD9 conjugate) was then stored at 48C until use.
Preparation of immunostrips
The LFIA was carried out in a dipstick format. The
nitrocellulose membrane (25 mm wide) was incorpora-
ted into the plastic backing to give robustness to the
340membrane. The test zone of the strip was prepared
dispensing a desired volume of 1 mg/mL anti-tetraspanin
and anti-IgG to form the test and control lines, respec-
tively, with the dispenser IsoFlow onto NC membrane at
a dispensing rate of 0.100 mL/mm and was dried for
34520 min at 378C. The sample pad and the absorbent pad
were then settled onto the backing card with an overlap
between them of around 2 mm. The complete strip was
cut into individual 4-mm strips.
LFIA procedure
350For dipstick analysis, purified exosome samples prepared
in running buffer were transferred into the microtube
containing AuNPs!antibody conjugate and homogenized
(final volume 100 mL). The dipstick was added and the
sample allowed to run for 15 min. The performance of
355the immunostrip relied on non-competitive assay formats.
Exosomes in the sample were sandwiched between
an anti-tetraspanin antibody immobilized on the strip
(Test line, T) and the AuNP-conjugated antibody. The
unbound AuNP-conjugates migrated further to be cap-
360tured with the anti-mouse immunoglobulin antibodies
(control, C) for system functional verification (Fig. 1).
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Results and discussion
Exosome characterization
Exosomes purified from cell culture supernatants of the
365 human melanoma cell line Ma-Mel-86c by sequential
centrifugation were characterized for expression of differ-
ent tetraspanins. Ma-Mel-86c exosomes were highly enric-
hed in CD81 and CD9, but contained lower amounts of
CD63 than whole cell lysates (Fig. 2a). Visualization of the
370 purified vesicles by transmission electron microscopy
(TEM) showed a round shape with a diameter ranging
between 50 and 150 nm (Fig. 2b). The average size
recorded by dynamic light scattering (DLS) was 206 nm
(PDI$0.290) for fresh samples and 177 nm (PDI$
375 0.226) for lyophilized samples. The results showed a z-
potential of #30 mV and #34 mV for fresh and lyophi-
lized samples, respectively, indicating that lyophilization
did not cause exosome aggregation. Exosome size and
stability during storage in fresh and lyophilized samples
380 were analysed, at 48C and #208C. The size of exosomes
did not change during the first week of storage at 48C in
lyophilized samples but some aggregates appeared in fresh
samples during that period of time (680 nm, PDI$0.587;
z-potential:#12 mV) (Fig. 2c).When samples were stored
385 at #208C, the exosomes remained stable for at least 9
months (data not shown). Both plasma and urine com-
mercial exosomes were also analysed by DLS (Supple-
mentary Fig. 3).
Exosomes detection by in-house ELISA
390 In order to test the availability of different tetraspanin
epitopes simultaneously in the same sample of exosomes,
several combinations of antibodies recognizing CD9,
CD81 and CD63 were assayed in ELISA experiments
with a constant concentration of exosomes derived from
395Ma-Mel-86c. Different concentrations of capture and
detection antibodies were assessed, and different wash
and incubation buffers were also tested. Optimal results
were obtained when the capture antibody was used at
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Fig. 1. Schematic view of the experimental procedure for exosomes detection. (a) Schematic representation of the ELISA set up for
exosomes detection. Here, each reagent is added in sequential steps. (b) Schematic representation of the lateral flow immunoassay
dipstick. (1) Specific antibodies against tetraspanins (test, T) and anti-mouse immunoglobulin antibodies (control, C) are immobilized
on the membrane. (2) Exosomes, if present in the sample, are detected by the detection probes (AuNP-conjugated antibodies). (3) As the
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Fig. 2. Metastatic melanoma exosome characterization. (a)
Western blot: Ma-Mel-86c lysates (L) and exosomes (E) were
prepared, run in SDS-PAGE and analysed by western blot using
the indicated antibodies. (b) TEM image: Exosomes from Ma-
Mel-86c cells were negatively stained with 2% phosphotungstic
acid and analysed by electron microscopy. Bar: 100 nm. (c)
Hydrodynamic size distribution profiles: Lyophilized and fresh
Ma-Mel-86c-derived exosomes (as indicated) were analysed in a
Zetasizer for their size distribution. The graph shows 1 reading
representative of 3.
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5 mg/mL in 100 mM sodium borate buffer, pH 9, while
400 the exosomes were more stable in HEPES-buffered saline,
both for washes and incubations. Different biotinylated
antibody concentrations were also tested for detection.
Biotinylated anti-CD9 (VJ1/20), anti-CD81 (5A6) or
anti-CD63 (Tea3/18) mAbs were compared as shown in
405 Fig. 3; the pair of antibodies that produced the best
signal-to-noise ratio (sample/blank) was anti-CD81 as cap-
ture mAb and anti-CD9 (1:1000) for detection. Mixtures
of several antibodies against tetraspanins were tested as
capture agents, but they did not improve the results
410 obtained when anti-CD81 alone was used as capture
antibody (data not shown).
Different concentrations of exosomes purified from
cell culture supernatants were tested using anti-CD81
capture antibody and biotinylated anti-CD9 detection
415 antibody, showing a linear dose response in the range of
14 to 2 mg/mL of exosomes (Fig. 4).
Characterization of nanoparticle!mAb conjugates
Since the biotinylated anti-CD9 antibody (VJ1/20) was
the most efficient detection antibody for exosomes in
420 the ELISA experiments, this antibody was selected for
detection for the LFIA. The protocol followed to con-
jugate the anti-CD9 antibody with AuNP is described in
the Methods section.
DLS measurements were carried out to confirm the
425 conjugation reaction between the gold nanoparticles and
the antibody. This technique allows monitoring the size
variation of the nanoparticles after the conjugation
reaction. The results show that the hydrodynamic size of
the AuNP!anti-CD9 conjugate was 56 nm (PDI 0.172).
430 To determine the stability of the conjugated antibody,
z-potential measures were carried out. The results showed
a z-potential of#17 mV for AuNP!anti-CD9, indicating
that the conjugates had enough repulsion to keep the
particles apart and, thus, were stable.
435LFIA development
Initially, an LFIA system was developed following the
optimal pattern obtained by ELISA. Thus, anti-CD81
monoclonal antibody (Clone 5A6) was dispensed onto
the membrane as capture antibody and anti-CD9 mono-
440clonal antibody (Clone VJ1/20) was conjugated with
AuNP as detection probe. The system was tested with
plasma exosomes and Ma-Mel-86c exosomes. Surpris-
ingly, despite the ELISA results, this system was unable
to detect exosomes isolated from melanoma cell culture
445supernatant. In contrast, exosomes isolated from human
plasma could be detected with the naked eye at levels as
low as 5 mg, by using LFIA system as shown in Fig. 5.
Different competition events and steric effects may
occur in ELISA and LFIA, which could explain this
450discrepancy. In ELISA, exosomes are captured by anti-
bodies immobilized on a surface, so that epitopes on the
opposite side of the exosome would be available for
binding with the detection antibody. In contrast, in
LFIA, exosomes are first bound to the detection anti-
455body, which is normally present in excess. This step
occurs in the buffer solution, and therefore, the whole
surface of the exosome is accessible to be covered by
antibody. In the case of Ma-Mel-86c cells, exosomes are
expected to be completely surrounded by antibody, since
460CD9 is especially abundant in these EVs (Fig. 2a) and the
CD81 capture antibody may not be able to access
epitopes due to steric hindrance. In fact, when Ma-Mel-
86c exosomes were present in the assay, the intensity of
the control line was in general lower than in the blank
465under the same conditions (Fig. 5a and b), suggesting
that AuNP!CD9 had been depleted by an extensive
binding to the exosome and, in consequence, there was
less excess of antibody available to bind at the control
line.
470Therefore, the differences in protein composition, loca-
lization and density of tetraspanins at the exosome
surface between these types of exosomes can markedly
influence their detection in LFIA.
In view of these results, an alternative tetraspanin
475LFIA system was developed. ELISA data suggested that
the antibody combination of anti-CD9 as capture and
anti-CD63 as detection could also be functional, despite
a higher background signal in ELISA (Fig. 3). The
conjugation of anti-CD63 antibody with AuNP was car-
480ried out following the protocol described in the Methods
section, and the corresponding increase in hydrodynamic
diameter over the naked AuNP and the absence of
aggregates were checked by DLS. The results show that
the hydrodynamic size of the AuNP!anti-CD63 was
Fig. 3. Comparison of exosome detection using different anti-
bodies by ELISA. A constant concentration of Ma-Mel-86c
purified exosomes was used in ELISA experiments in which
different combinations of capture and detection antibodies
(indicated at the bottom and top of the figure, respectively)
were used. The concentrations used for the different capture
(5 mg/mL) and detection (anti-CD9 1:1000, anti-CD81 1:1000
and anti-CD63 1:500) antibodies had been optimized in a
different experiment. Blank wells had incubation with both
capture and detection antibodies but not with exosome samples.
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485 64 nm (PDI$0.117), with a z-potential of #23 mV,
suggesting that, as in the case of AuNP!anti-CD9, the
complexes were stable.
This pair of antibodies (anti-CD9 as capture antibody
and anti-CD63 as detection antibody) had a high back-
490 ground in the absence of exosomes, in ELISA, but not
in the LFIA system. With this combination, we were
able to detect exosomes from melanoma cell supernatants
and human plasma (Fig. 6b and c). Moreover, this
combination of anti-tetraspanin antibodies also allowed
495 the detection of urine exosomes (Fig. 6d), which have
been reported to contain very small amounts of the
tetraspanin CD81 (38). Exosome-depleted plasma was
used as negative control (Fig. 6e).
Given the recent discovery of EVs as potential bio-
500 markers, convenient diagnosis devices need to be devel-
oped. The results shown in Fig. 6 establish a proof of
concept for the development of rapid tests for the
detection of exosomes with clinical applications.
With the aim of giving an estimate of the analytical
505potential of these platforms, we have carried out a
quantitation of how the increase in intensity at the test
line varies with the concentration of exosomes. This
correlation allows us to estimate the linear useful range
and sensitivity of the measurements. Since most of the
510time the final end-user of the in vitro test will not have
information about the abundance of tetraspanin domains
on the surface of the exosomes tested, the immunoassay
was developed immobilizing a mixture of anti-CD9 and
anti-CD81 (1:1) at the test line, in order to ensure the
515capture at all the possible exosome sources, and keeping
AuNP!anti-CD63 as detection probe. This guarantees
that our LFIA strip will be able to detect exosomes
purified from a wide range of fluids, although for Ma-
Mel-86c exosomes, this combination of mAbs in the test
520line did not show any advantage when compared with
anti-CD9 alone (Supplementary Fig. 4).
Once the test with exosomes purified fromMa-Mel-86c
supernatants was run, the line intensities were recorded by
scanning the images using a Lexmark 4800 scan and the
525optical density was measured using ImageJ 1.48 v soft-
ware. All the assays were performed in triplicates and
scanned in grey scale with a scan resolution of 2,400 ppp
(Fig. 7). The colour of test lines displayed clear gradient
according to the concentration of exosomes, although the
530test line started to saturate at quantities of 1.44"108
exosomes/mL. Non-specific binding was not observed in
the absence of exosomes. The limit of detection (LOD),
calculated from the calibration curve (the concentration
corresponding to 3 times the standard deviation of the
535intercept) (39), was 8.54"105 exosomes/mL.
Our approach shows a positive correlation between the
concentration of exosomes purified from melanoma cell
culture supernatant and the intensity of signal. Similar
behaviour is expected with exosomes from the commer-
540cial source or purified tissue fluid. Hence, to our knowl-
edge, this is the first time that such a novel method for the
detection of exosomes had been developed (13,14).
Although the analytical features described here lay the
ground for the development of clinical applications at
Fig. 5. Photograph of the test strips of LFIA for melanoma cell
culture supernatant and plasma exosomes using anti-CD81 as
capture antibody and AuNP!anti-CD9 as detection probe. (a)
Blank: running buffer. (b) Photograph of the strip after adding
20 mg of Ma-Mel-86c exosomes. (c) Photograph of the strip
corresponding to 5 mg of plasma exosomes (HBM).
Fig. 6. Photograph of the test strips of LFIA using anti-CD9 as
capture antibody and AuNP!anti-CD63 as detection probe,
corresponding to: (a) Blank: running buffer. (b) 20 mg Ma-Mel-
86c exosomes. (c) 20mg of plasma exosomes (HBM). (d) 20 mg of
urine exosomes (HBM). (e) Exosome-depleted plasma.
Fig. 4. Titration of exosome detection by ELISA. Varying
amounts of Ma-Mel-86c-derived exosomes were analysed by
ELISA using anti-CD81 (5A6) as capture antibody and
biotinylated anti-CD9 (J1/20) as detection antibody. The data
points are the average of 2 replicates.
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545 screening, diagnostics or prognostics, the aim of this
manuscript was to introduce for the first time the use of
LFIA to detect vesicles and more work should follow to
improve the applications in a POC setting. In any case, in
order to have a POC, clinically suited device, specific
550 markers for specific diseases, when appropriately de-
scribed, should also be included in the LFIA device.
Lastly, in our system, the possibility that EVs could
be associated with aggregated proteins from the culture
media or plasma materials like LDL (40) could not be
555 excluded. However, the data presented here prove that,
as the sample solution flows through the strip, EVs can
be recognized by a labelled tetraspanin and that this
immunocomplex can be captured afterwards by a second
tetraspanin immobilized on nitrocellulose.
560 Conclusions
In this study, we have described an in-house ELISA to
detect exosomes purified from cell culture supernatants
and developed several LFIA to detect exosomes from cell
culture supernatants as well as from commercial exo-
565 somes previously enriched from human plasma and urine.
Here, we have presented a novel lateral flow with a wide
range of applications. This assay has been applied for the
detection of exosomes purified from a metastatic mela-
noma cell line, with an LOD of 8.54"105 exosomes/mL.
570 The assay is easy to conduct, including by unskilled
operators, and the results can be checked in 15 min. This
work was carried out taking into account the hetero-
geneous composition of exosomes, in order to achieve a
universal wide-broad application LFIA system. With this
575 aim, we have chosen to use a blend of anti-CD9 and anti-
CD81 as capture antibodies to detect exosomes from
different sources. However, we have shown too that a
specialized LFIA for a specific exosome subpopulation
could be developed. In this sense, strips with anti-CD9
580 alone as capture antibody and AuNP!anti-CD63 as
detection probe lead to better results for Ma-Mel-86c
metastatic melanoma cells.
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